Financial news
Home
Knowledge Hub
U.S. steps up pharma, chip import probes; LVMH reports - what’s moving markets
2025-04-15 17:22:54

U.S. stock futures point higher, with markets focused on the trajectory of President Donald Trump’s tariff policy. The White House steps up probes into pharmaceutical and semiconductor imports, in a sign that the Trump administration could be eyeing tariffs on the sectors. Bank of America and Citigroup (NYSE:C) are due to be the latest lenders to report their quarterly earnings, while LVMH’s revenue disappoints expectations.


1. Futures tick up


U.S. stock futures edged higher on Tuesday, as investors assessed Trump’s tariff plans and awaited a raft of corporate earnings.


By 03:41 ET (07:41 GMT), the Dow futures contract had risen by 79 points, or 0.2%, S&P 500 futures had added 15 points, or 0.3%, and Nasdaq 100 futures had ticked up by 73 points, or 0.4%.


The main averages on Wall Street rose in the prior session, underpinned by the White House’s pause on reciprocal levies on a slew of tech-related products and comments from Trump that he was also considering some tariff relief for the auto industry.


Sentiment was bolstered by a Federal Reserve Bank of New York survey showing that medium- and long-term expectations for price increases were flat-to-down -- although near-term estimates rose.


Meanwhile, Fed Christopher Waller argued that the inflationary impact of the duties may be transitory as well. Still, he flagged caution around the growth outlook due to the trade taxes, saying they amount to “one of the biggest shocks to affect the U.S. economy in many decades.”


U.S. Treasuries gained, with yields -- which tend to move inversely to prices -- declining by between 7-15 basis points across the curve. A steep sell-off last week in the U.S. bond market, a key component of the plumbing of the global financial system, appeared to be one motive behind Trump’s decision to temporarily halt most of his elevated tariffs on most countries for 90 days.


2. U.S. intensifies probe into pharmaceutical, chip imports

The Trump administration has said it is kicking off investigations into imports of pharmaceuticals and semiconductors products, as it gauges whether to impose tariffs on these sectors.

According to Federal Register filings on Monday, the White House began the probes on April 1 and announced a 21-day comment period. It was the latest move by Trump to utilize a U.S. measure that allows for sectoral tariffs as a means of protecting industries seen as critical to national security.

The move comes after a slate of electronics largely imported from China were exempted from Trump’s punishing tariffs on Friday, but officials later suggested that the action would be temporary.

Trump has made tariffs one of the central policy pillars of the opening months of his second term in power, slapping aggressive duties on both friends and adversaries alike in bid to correct what he has deemed to be unfair trade practices. The average import levy charged by the U.S. has risen to roughly 25% from 2.5% in just a few months, economists have estimated.

3. More bank results ahead

Investors will have the chance to pour through more results from Wall Street banking giants on Tuesday.

Bank of America and Citigroup are due to release their latest quarterly earnings, following figures from a number of lenders this week.

Tariff-driven volatility in financial markets mostly boosted industry-wide equity trading returns in the first quarter, yet executives have warned that the duties could depress broader economic output and weigh on incomes in the months ahead.

On Monday, Goldman Sachs CEO David Solomon told analysts that "the prospect of a recession has increased with growing indications that economic activity is slowing down around the world," adding that the firm’s clients are concerned by "signficant near-term and longer-term uncertainty."

Beyond banks, Johnson and Johnson will be one of the first major non-financial reports to be unveiled during the nascent first-quarter earnings season, and could provide a glimpse into the possible impact on the pharma titan of the Trump administration’s trade policies and push to downsize the federal government.

4. LVMH earnings disappoint

LVMH (EPA:LVMH) has reported first-quarter revenue that fell short of expectations, as U.S. shoppers reined in spending on beauty products and drinks and demand in China remained tepid.

Sales during the January to March period slipped by 3%, missing estimates for an expansion of 2%, potentially indicating a tough upcoming year for the luxury sector as Trump’s tariffs threaten economic activity and customers’ shopping appetites.

U.S.-listed depositary receipts (OTC:LVMUY) in the fashion and beverage behemoth, whose brands include Bulgari jewellery and Hennessy cognac, dropped by as much as 7.5% following the release.

Speaking to analysts, LVMH finance chief Cecile Cabanis noted that recent trade tensions have complicated the operating environment for the business, adding that "parameters are changing every hour."

5. Oil inches higher

Oil prices advanced, supported by optimism over the Trump administration’s recent tariff exemptions as well as a rebound in Chinese crude oil imports.

At 03:42 ET, Brent futures climbed 0.5% to $65.23 a barrel. U.S. West Texas Intermediate crude futures rose 0.6% to $61.88 per barrel.

Data released on Monday showed that China’s crude oil imports in March were up nearly 5% from a year earlier, as arrivals of Iranian oil surged in anticipation of tighter U.S. sanctions enforcement.

Elsewhere, gold prices were below a new record high notched on Monday, while the U.S. dollar firmed against a basket of currency peers and Bitcoin gained more than 1%.